West Pharmaceutical Services, Inc. $WST Shares Sold by Findlay Park Partners LLP

Findlay Park Partners LLP trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 816,606 shares of the medical instruments supplier’s stock after selling 29,600 shares during the period. West Pharmaceutical Services accounts for approximately 1.8% of Findlay Park Partners LLP’s holdings, making the stock its 22nd biggest position. Findlay Park Partners LLP owned approximately 1.14% of West Pharmaceutical Services worth $178,673,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Generation Investment Management LLP acquired a new stake in shares of West Pharmaceutical Services in the second quarter valued at $255,072,000. Durable Capital Partners LP grew its holdings in shares of West Pharmaceutical Services by 146.8% in the 1st quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier’s stock worth $352,190,000 after acquiring an additional 935,721 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of West Pharmaceutical Services by 57.8% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 997,882 shares of the medical instruments supplier’s stock worth $223,406,000 after purchasing an additional 365,575 shares during the period. Nuveen LLC purchased a new stake in West Pharmaceutical Services during the first quarter valued at about $79,255,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of West Pharmaceutical Services by 43.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,134,706 shares of the medical instruments supplier’s stock worth $254,038,000 after buying an additional 343,997 shares during the period. Institutional investors own 93.90% of the company’s stock.

Analyst Ratings Changes

WST has been the topic of several research analyst reports. Barclays lifted their price objective on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Monday, October 27th. UBS Group lifted their target price on West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, October 24th. KeyCorp increased their price target on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, October 24th. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Tuesday, October 14th. Finally, Cowen began coverage on shares of West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $349.20.

West Pharmaceutical Services Stock Down 1.2%

WST stock opened at $277.36 on Thursday. The firm has a market cap of $19.95 billion, a PE ratio of 41.09, a PEG ratio of 4.09 and a beta of 1.08. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90. The company has a fifty day simple moving average of $270.53 and a 200 day simple moving average of $244.92. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The company had revenue of $804.60 million during the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.85 earnings per share. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.